Icon

IDHIFA (nda209606)- (EQ 50MG BASE,EQ 100MG BASE)

ENASIDENIB MESYLATE BRISTOL MYERS SQUIBB
EQ 50MG BASE,EQ 100MG BASE
No No
2034-Sep-16 2022-Aug-01
2024-Aug-01 None
None No
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 50MG BASE ** ** - - -
EQ 100MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.